This is a multi-center, prospective cohort study that collects only diagnostic and therapeutic data in subjects but does not interfere with treatment.

The study aims to assess blood pressure and lipid levels, the use of lipid-lowering and antihypertensive drugs, and treatment compliance and adverse events in hypertensive outpatients of 30 hospitals of different levels, following them up for 1 and 3 months after treatment, respectively. The study would reveal the compliance of blood pressure and lipid levels in hypertensive patients under management of hospitals at different levels, and analyze factors affecting blood pressure or lipid levels associated with treatment compliance. Therefore, the study would provide clinical data from the real world for future prevention and control of CVD in China.

Inclusion Criteria:

Patients meeting the following criteria will be included:

1. Age ≥18 years, male or female;
2. Agreement for blood pressure and lipid testing;
3. Initial diagnosis of primary hypertension, with blood pressure conforming to the diagnostic criteria of the 2018 Guidelines for the Prevention and Treatment of Hypertension in China [14] (with no antihypertensive drugs, SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg after three tests performed on different days); or a history of primary hypertension but incompliant blood pressure;
4. Willingness to participate in the study and signing of informed consent.

Exclusion Criteria:

• Patients meeting the following criteria will be excluded:

  1. Involvement in an interventional clinical research;
  2. Pregnancy or lactation in women;
  3. Complication with malignant tumors;
  4. Diagnosis of non-primary hypertension by researchers;
  5. Impaired cognitive ability;
  6. Researchers believing that the patients have other conditions not suitable for the study.

Initial diagnosis of primary hypertension